Tang Capital Management’s UroGen Pharma URGN Stock Holding History

Tang Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-350,000	Closed	-$6.29M	–	56
2026 Q1	$6.29M	Hold	350,000	–	–	0.32%	33
2025 Q4	$8.2M	Sell	350,000 -650,000	-65%	-$14.1M	0.4%	45
2025 Q3	$19.9M	Hold	1,000,000	–	–	0.77%	36
2025 Q2	$13.7M	Buy	+1,000,000	New	+$9.6M	0.69%	41

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Tang Capital Management's URGN Position: Q2 2026 in Review

Tang Capital Management sold out of UroGen Pharma (URGN) in Q2 2026, closing a stake of 350,000 shares — an estimated $6.29M sold.

Tang Capital Management first reported a position in URGN in Q2 2025 and held it in 4 quarters. The position peaked at $19.9M in Q3 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Tang Capital Management reported no remaining UroGen Pharma position as of Q2 2026 after selling out during the quarter.
Tang Capital Management sold 350,000 UroGen Pharma shares in Q2 2026, an estimated $6.29M.
Tang Capital Management first reported a position in UroGen Pharma in Q2 2025 and held it in 4 quarters.
Tang Capital Management's UroGen Pharma position peaked at $19.9M in Q3 2025.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Tang Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.